


RESEARCH ARTICLE

Genetic reanalysis of patients with a difference of sex development carrying the *NR5A1/SF-1* variant p.Gly146Ala has discovered other likely disease-causing variations

Idoia Martinez de Lapiscina^{1,2,3,4,5,6*}, Chrysanthi Kouri^{1,2,7}, Josu Aurrekoetxea^{8,9}, Mirian Sanchez³, Rawda Naamneh Elzenaty^{1,2,7}, Kay-Sara Sauter^{1,2}, Núria Camats^{5,10}, Gema Grau^{3,6,11}, Itxaso Rica^{3,4,5,6,11}, Amaia Rodriguez^{3,11}, Amaia Vela^{3,4,5,6,11}, Alicia Cortazar^{4,12}, Maria Concepción Alonso-Cerezo¹³, Pilar Bahillo¹⁴, Laura Bertholt¹⁵, Isabel Esteve¹⁶, Luis Castaño^{3,4,5,6,9,11}, Christa E. Flück^{1,2}



OPEN ACCESS

Citation: Martinez de Lapiscina I, Kouri C, Aurrekoetxea J, Sanchez M, Naamneh Elzenaty R, Sauter K-S, et al. (2023) Genetic reanalysis of patients with a difference of sex development carrying the *NR5A1/SF-1* variant p.Gly146Ala has discovered other likely disease-causing variations. PLoS ONE 18(7): e0287515. <https://doi.org/10.1371/journal.pone.0287515>

Editor: Jean-Marc A Lobaccaro, Université Clermont Auvergne - Faculté de Biologie, FRANCE

Received: February 13, 2023

Accepted: June 7, 2023

Published: July 11, 2023

Copyright: © 2023 Martinez de Lapiscina et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and all novel variants are deposited with ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>).

Funding: This work has been supported by the University of the Basque Country (UPV-EHU) (Spain) (IT1739-22) and by the Swiss National Science Foundation (320030-197725). IM is

1 Department of Pediatrics, Inselspital, Pediatric Endocrinology, Diabetology and Metabolism, Bern University Hospital, University of Bern, Bern, Switzerland, **2** Department for BioMedical Research, University of Bern, Bern, Switzerland, **3** Biocruces Bizkaia Health Research Institute, Research into the Genetics and Control of Diabetes and other Endocrine Disorders, Cruces University Hospital, Barakaldo, Spain, **4** Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain, **5** Instituto de Salud Carlos III, CIBER de Enfermedades Raras (CIBERER), Madrid, Spain, **6** Endo-ERN, Amsterdam, The Netherlands, **7** Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland, **8** Biocruces Bizkaia Health Research Institute, Research Group of Medical Oncology, Cruces University Hospital, Barakaldo, Spain, **9** University of the Basque Country (UPV-EHU), Leioa, Spain, **10** Vall d'Hebron Research Institute (VHIR), Growth and Development group, Hospital Universitari Vall d'Hebron, Barcelona, Spain, **11** Department of Pediatric Endocrinology, Cruces University Hospital, Barakaldo Spain, **12** Endocrinology Department, Cruces University Hospital, Barakaldo, Spain, **13** La Princesa University Hospital, Madrid, Spain, **14** Department of Pediatrics, Pediatric Endocrinology Unit, x Clinic University Hospital of Valladolid, Valladolid, Spain, **15** Pediatric Endocrinology Department, Marques de Valdecilla University Hospital, Santander, Spain, **16** Endocrinology Section, Gender Identity Unit, Regional University Hospital of Malaga, Malaga, Spain

* These authors contributed equally to this work.

* idoia.martinezdelapiscina@unibe.ch

Abstract

NR5A1/SF-1 (Steroidogenic factor-1) variants may cause mild to severe differences of sex development (DSD) or may be found in healthy carriers. The *NR5A1/SF-1* c.437G>C/p. Gly146Ala variant is common in individuals with a DSD and has been suggested to act as a susceptibility factor for adrenal disease or cryptorchidism. Since the allele frequency is high in the general population, and the functional testing of the p.Gly146Ala variant revealed inconclusive results, the disease-causing effect of this variant has been questioned. However, a role as a disease modifier is still possible given that oligogenic inheritance has been described in patients with *NR5A1/SF-1* variants. Therefore, we performed next generation sequencing (NGS) in 13 DSD individuals harboring the *NR5A1/SF-1* p.Gly146Ala variant to search for other DSD-causing variants and clarify the function of this variant for the phenotype of the carriers. Panel and whole-exome sequencing was performed, and data were analyzed with a filtering algorithm for detecting variants in *NR5A1*- and DSD-related genes.

supported by a Postdoctoral Fellowship Grant from the Education Department of Basque Government (Spain). JA is supported by ASONMEC (Asociacion de Oncologia Medica del Hospital de Cruces) (Spain). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

The phenotype of the studied individuals ranged from scrotal hypospadias and ambiguous genitalia in 46,XY DSD to opposite sex in both 46,XY and 46,XX. In nine subjects we identified either a clearly pathogenic DSD gene variant (e.g. in *AR*) or one to four potentially deleterious variants that likely explain the observed phenotype alone (e.g. in *FGFR3*, *CHD7*). Our study shows that most individuals carrying the *NR5A1*/SF-1 p.Gly146Ala variant, harbor at least one other deleterious gene variant which can explain the DSD phenotype. This finding confirms that the *NR5A1*/SF-1 p.Gly146Ala variant may not contribute to the pathogenesis of DSD and qualifies as a benign polymorphism. Thus, individuals, in whom the *NR5A1*/SF-1 p.Gly146Ala gene variant has been identified as the underlying genetic cause for their DSD in the past, should be re-evaluated with a NGS method to reveal the real genetic diagnosis.

Introduction

Typical sex development depends on a tightly controlled network of genes and pathways [1–3]. Any perturbation in this very complex biological event, which involves genetic and hormonal processes, may result in atypical sex development and leads to a broad range of differences of sex development (DSD) in humans, also known as variations of sex characteristics (VSC) [4]. The *NR5A1* gene, which encodes the steroidogenic factor 1 (SF-1), regulates multiple genes implicated in adrenal development, gonadal determination and differentiation, steroidogenesis, and reproduction [5]. Since the identification of the first *NR5A1*/SF-1 variation in a 46,XY patient with primary adrenal failure and complete gonadal dysgenesis [6], the gonadal and reproductive phenotype associated with *NR5A1*/SF-1 variants has broadened including 46,XY and 46,XX cases with sex reversal to minor anomalies such as hypospadias or even healthy carriers, whereas adrenal failure has only been found in very rare cases [7,8].

Currently, 291 different *NR5A1*/SF-1 variants are reported in the Human Gene Mutation Database (HGMD, October 2022). Variants include missense/nonsense, indels, small insertions/deletions, complete gene deletions or splice-site variants that are scattered throughout the whole gene without obvious hot spots. According to ACMG (American College of Medical Genetics and Genomics) classification [9], described variants may qualify as (likely) pathogenic or (likely) benign, and several are variants of unknown significance (VUS).

The nonsynonymous *NR5A1*/SF-1 c.437G>C/p.Gly146Ala (rs1110061) variant has been first described in a group of Japanese patients presenting with a series of adrenal diseases such as Cushing's syndrome or non-functioning adrenocortical adenoma [10]. In this context, WuQiang et al. reported that the p.Gly146Ala variant slightly impairs the transactivation ability of adrenal and ovary specific gene promoters but does not affect cofactor interaction and cellular localization [10]. Later, it has been proposed to act as a susceptibility factor for cryptorchidism [11], isolated micropenis [12,13], spermatogenic failure [14,15], primary ovarian insufficiency (POI) [16] and type 2 diabetes [17]. The p.Gly146Ala variant is common among individuals with a 46,XY DSD with a prevalence varying between 6.8 and 31% [18,19]. However, the minor allele frequency (MAF) (C allele) is also high in the overall control population (23.5%, gnomAD v3.1.2). Specifically, its MAF is increased approximately by 1.3–3-fold in the East Asian and the African control populations, whereas it is only present in 1% of the European control population (gnomAD v3.1.2). Moreover, in vitro studies of transcriptional activity of the *NR5A1*/SF-1 p.Gly146Ala variant on several target promoters in various cell models

found unaltered wild-type functionality [18,20]. In fact, some patients who carry severe, pathogenic *NR5A1*/SF-1 variants in compound heterozygous state with the p.Gly146Ala variant, do not phenotypically differ from individuals carrying the severe variant only [8,19–25]. The DSD causing effect of the *NR5A1*/SF-1 p.Gly146Ala variant is therefore in doubt. However, given that oligogenic inheritance has been suggested for explaining the broad phenotype observed in individuals and families with *NR5A1*/SF-1 gene variants [26–32], the p.Gly146Ala variant might play a role as co-regulator or disease modifier of sexual development.

The aim of this study was therefore, to elucidate the role of the *NR5A1*/SF-1 p.Gly146Ala variant on sexual development. We studied 13 DSD patients carrying this variant by next generation sequencing (NGS). Specifically, we searched for other DSD-causing variants and their pathogenicity in order to assess the effect of the *NR5A1*/SF-1 p.Gly146Ala variant on the phenotype of its carriers.

Patients and methods

Patients and ethical approval

We recruited 13 pediatric DSD individuals carrying the *NR5A1*/SF-1 p.Gly146Ala variant from a larger cohort of 124 DSD patients (98 patients with a 46,XY karyotype, 24 with 46,XX, and 2 patients with a 45X/46,XY karyotype) collected at the Biocruces Bizkaia Health Research Institute (Barakaldo, Spain). Clinical data were provided by the caring clinicians (Table 1 and S2 Table). The study was approved by the ethics committee for clinical research of Euskadi (CEIC-E), Spain. Written informed consent was provided by the parents of the studied children.

Nine 46,XY DSD and four 46,XX DSD patients carrying the p.Gly146Ala variant in the *NR5A1*/SF-1 gene were analyzed using whole exome sequencing (WES) or a targeted gene panel comprised of 48 genes associated with sex determination, sex differentiation and hypogonadism (S1 Table).

Genetic analysis

Genomic DNA from patients was extracted from peripheral blood leukocytes using the Mag-Purix 12S system (Zinexts Life Science Corp.). DNA purity and concentration were determined using a Qubit 2.0 fluorometer (Thermo Fisher Scientific). Blood or DNA of family members of any index cases was not available for testing.

Initial characterization for the *NR5A1*/SF-1 p.Gly146Ala variant was done by a DSD specific panel. Additional NGS was performed by WES (Fig 1A). For WES, libraries were prepared using the Illumina DNA/RNA Prep Tagmentation PCR reagents (Illumina) and Illumina Exome Panel (CEX) according to the manufacturer's instructions. The resulting libraries were subjected to paired-end sequencing on a NovaSeq 6000 System (Illumina). Raw data were then converted to FastQ files for computational analysis, which included read alignment to the human genome reference sequence (GRCh38), duplicate marking, base quality score recalibration, indel realignment, and variant calling with an in-house bioinformatics pipeline using BWA-MEM [34] and GATK [35] software. Variants were annotated with ANNOVAR [36] and filtration process of the exonic variants was performed using R software (R 4.2.0). Variant filtration was performed following specific steps as given in Fig 1B.

These steps included the filtration of WES data by a DSD- and *NR5A1*-related gene list. These disease-tailored lists were updated from previously reported work (DSD-gene list, N = 584; *NR5A1*-related gene list, N = 628) [26] (Fig 1B, step a). Then, we kept the resulting variants with all type of predicted consequences (e.g. nonsynonymous, frameshift deletion, stop/gain), but synonymous, and with a number of reads above or equal to 20 (Fig 1B steps b

Table 1. Phenotype of the DSD patients harboring the *NR5A1*/SF-1 p.Gly146Ala variant. Further details including biochemical data are given in S2 Table.

Patient/ Origin ^a	Karyotype/Sex assignment ^b	Zygosity ^c	Age at diagnosis	External genital phenotype ^d	Internal phenotype	Gonadal/reproductive function	Other organ anomalies
1 ¹	46,XY/M	Het	1y	Mild	Laparoscopy: absence of female organs and gonadal tissue. Histology: undifferentiated tissue.	1y, abnormal (no T response to hCG)	No
2 ²	46,XX/M	Het	6y	Opposite sex	US: no Müllerian ducts. Histology: infantile ovary with follicular cysts, fallopian tube, atrophic uterus, mesonephric remnant.	hCG test with hyperandrogenic reaction for typical male	No
3 ²	46,XY/M	Het	9y	Severe	US: inguinal testes (right 0.5cc; left 0.6cc).	9y, normal hCG test	No
4 ²	46,XX/M	Hom	6y	Opposite sex	Laparoscopy: bilateral gonads in inguinal canal and iliac area, atrophic uterus. No Müllerian ducts. Histology: bilateral ovotestes.	hCG test with hyperandrogenic reaction for typical male	No
5 ²	46,XX/M	Hom	3y	Opposite sex	US: inguinal bilateral gonads (1ml), no Müllerian ducts. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	hCG test with hyperandrogenic reaction for typical male	No
6 ²	46,XY/M	Het	2y	Mild	MRI: absence of uterus and ovaries.	2y, normal baseline and hCG test	Anal agenesis, iron deficiency
7 ²	46,XY/M	Hom	6y	Severe	US: scrotal right testis (15x9mm), inguinal left testis (13x6mm).	6y, normal baseline and hCG test	No
8 ²	46,XY/F	Het	7y	Opposite sex	US: vaginal opening, no uterus. Histology of the gonads: testicular tissue at age 7 and 24.	35y, abnormal (high gonadotropins and low T)	No
9 ²	46,XX/M	Hom	3y	Opposite sex	US: prepubertal uterus. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	Prepubertal	No
10 ¹	46,XY/M	Het	11mo	Mild	US: normal size intrascrotal testes.	14y, normal (normal T and gonadotropins)	No
11 ³	46,XY/M	Het	At birth	Severe	ND	ND	Left renal agenesis, lipomeningocele
12 ¹	46,XY/F	Het	15y	Opposite sex	Infantile uterus and ovaries by ultrasound.	ND	Abdominal obesity
13 ¹	46,XY/M	Het	7d	Severe	US: normal uterus, absence of gonads.	Abnormal (high gonadotropins and normal T)	No

d, days; F, female; hCG, human chorionic gonadotropin; M, male; mo, months; MRI, magnetic resonance imaging; ND, not determined; T, testosterone; US, ultrasound; y, years.

^aOrigin of the patients:

¹Spanish;

²African;

³Asian.

^bNone of the patients was sex re-assigned.

^cZygosity of the *NR5A1*/SF-1 p.Gly146Ala variant identified by targeted gene panel.

^dSeverity of the DSD was based on karyotype and the clinical assessment of the external genitalia at birth or before genital surgery, and grouped in four categories: 1) typical for karyotypic sex, 2) mild DSD (isolated abnormal meatal opening, cryptorchidism or micropenis) 3) severe DSD (external genital features different from the typical external genitalia like XY karyotype with perineal meatal opening, micropenis and labioscrotal gonads), and 4) opposite sex (complete sex reversed external genitalia in relation to karyotype) [33].

<https://doi.org/10.1371/journal.pone.0287515.t001>

and c) [37]. Next, we filtered to include variants with a $MAF \leq 0.01$ according to gnomAD (v3.1.2) and depending on the origin and karyotype of the patient (Fig 1B, step d). In step e, we confirmed the correct annotation, location of variants and zygosity by checking their alignment data in IGV (Integrative Genomics Viewer). Finally, we predicted the possible effect of




Fig 1. Algorithm of genetic workup. A. Mode of genetic analysis, e.g. panel and whole exome sequencing (WES). Two patients were identified with pathogenic variants in *LHCGR* and *AR* by panel analysis and were not further analyzed by whole-exome sequencing (WES). B. Filtering algorithm of genetic data. Steps used for variant filtering after WES of eleven DSD patients harboring the *NR5A1*/SF-1 p.Gly146Ala variant are depicted (letters a to f). Final candidates and their possible impact are listed and characterized in Table 2 and S3 Table.

<https://doi.org/10.1371/journal.pone.0287515.g001>

the identified variant (see below) (Fig 1B, step f). Variants were confirmed by visual examination using the IGV (Integrative Genomics Viewer) browser [38,39].

For the targeted DSD-gene panel analysis, preparation of the libraries and sequencing have been described elsewhere [27]. For variant filtration after panel analysis, same steps b to f were followed (Fig 1B).

In silico analyses and variant classification

We predicted the possible effect of identified nonsynonymous genetic variants on the structure and function of the protein using Polyphen-2, (Polymorphism Phenotyping v2), Panther (Protein ANalysis THrough Evolutionary Relationships), SNPs and GO, CADD (Combined Annotation Dependent Depletion) and the calibrated scores given by VarSome [40] for Revel (Rare Exome Variant Ensemble Learner), SIFT (Scale-invariant feature transform), Provean (Protein Variation Effect Analyzer), Mutation taster and M-CAP (Mendelian Clinically Applicable Pathogenicity) (see S3 Table). Variants were classified for pathogenicity according to the standards and guidelines of the ACMG [9] using VarSome. We considered variants as candidates when classified as pathogenic, likely pathogenic or as VUS by the ACMG criteria or when classified as pathogenic or VUS by at least 7 out of 9 prediction programs. Previously reported clinical associations were searched in ClinVar and HGMD databases. In addition, the literature (e.g. PubMed) was searched for evidence of relationship with DSD, sex development and the specific clinical phenotype of each study subject. We explored the possible disease-causing variants' combinations using ORVAL (Oligogenic Resource for Variant AnaLysis) [41].

Results and discussion

In a random cohort of 124 subjects with a DSD, we identified the *NR5A1*/SF-1 p.Gly146Ala variant in 13 individuals (10.5%). The prevalence in 46,XY DSD subjects was 9.2% (9/98), and was in line with previously reported prevalence in this population [18,19]. Prevalence was higher in 46,XX DSD (4/24, 16.7%). Of the 13 studied subjects, four were homozygous and nine heterozygous for the *NR5A1*/SF-1 p.Gly146Ala variant. The phenotype of the individuals ranged from typical for karyotype to mild and severe atypical in 46,XY as well as opposite sex in both 46,XY and 46,XX (Fig 2). Patients were of African (7/13), Spanish (4/13) and Asian (2/13) origin. A summary of the clinical and biochemical characteristics of the patients is given in Table 1 and S2 Table. An overview of the identified genes of our study subjects that likely play a role for the DSD phenotype in a concerted way is given in Fig 3. In this Fig 3 the identified variants are shown within the network of established genes of sex determination and differentiation.

NGS performed in DSD individuals harboring the p.Gly146Ala variant in *NR5A1*/SF-1 revealed several deleterious/candidate variants that potentially explain the phenotype of the patients. Overall, we identified either a known pathogenic DSD variant or one to four potentially deleterious/candidate variants in 9 out of the 13 DSD individuals analyzed. A detailed summary of identified variants in other DSD-related genes is shown in Table 2 (further details in S3 and S4 Tables).

In two patients we detected variants in known DSD-causing genes with our targeted gene panel, e.g. *LHCGR* and *AR*. In 11 patients WES was performed and variants were filtered by candidate gene lists (Fig 1). Overall, the NGS analysis identified 63 variants categorized as (likely) pathogenic or VUS in 57 different genes, however further review of evidence of correlation with DSD, sex development and phenotype of each patient with literature reduced this number to 19 potentially deleterious/candidate variants in 17 genes in nine subjects. In eight 46,XY DSD individuals 1–4 variants were found in a total of 15 genes, while one 46,XX DSD





Fig 2. External genital phenotype of the 13 DSD patients harboring the *NR5A1*/SF-1 p.Gly146Ala variant shown with respect to their karyotype.

<https://doi.org/10.1371/journal.pone.0287515.g002>

person revealed two variants in two different genes (Table 2). All variants, identified either by gene panel or WES, but one (e.g. *LHCGR*), were detected in heterozygosis or hemizygos. Details of the rejected variants are given in S4 Table.

In patient 1 two frameshift deletions in genes *FGFR3* (c.1633_1634del; p.Cys545Hisfs*17) and *INSR* (c.660_661del; p.Pro220Hisfs*4) and a stop-gain variant in *ADAMTS16* (c.1822_1823del; p.His608*) were found and predicted to be likely pathogenic by the ACMG criteria. *FGFR3* is essential for testicular development in humans [44], while *INSR* and *ADAMTS16* are needed in murine genitourinary development and testicular differentiation, respectively [45,46]. Variants in *ADAMTS16* have also been reported in heterozygosis in two 46,XY females with complete gonadal dysgenesis and a 46,XY DSD patient with ambiguous genitalia [47]. Testing for a digenic combination network with ORVAL showed no variant interaction between *ADAMTS16* and *FGFR3*.

We detected four heterozygous missense variants in four genes in patient 3. These were *GLI2* (c.3528G>T; p.Gln1176His), *CDH7* (c.1623C>A; p.His541Gln), *MYO7A* (c.2882G>A; p.Gly961Asp) and *VDR* (c.176C>T; p.Thr59Ile). The variant in *GLI2* (c.3528G>T; p.Gln1176His) was rated as pathogenic by most of the *in silico* prediction tools and variants in additional genes were rated as VUS when analyzing according to pathogenicity guidelines. Variants in *GLI2* have been described in syndromic DSD patients together with short stature, primary hypogonadism, heart and craniofacial anomalies and 46,XY gonadal dysgenesis [48], as well as in 46,XY non-syndromic DSD manifesting with female external genitalia or with ambiguous genitalia [26,49,50]. Variants in *CHD7* have been previously associated with a broad range of 46,XY DSD phenotypes, including males with hypospadias or micropenis and individuals with female external genitalia [30,51]. *MYO7A* is overexpressed in male supporting



cells during gonadal development [52] and has been shown to be a SRY and SOX9 target gene [53], but, in DSD individuals it has been identified only in combination with *MAMLD1* [50,54]. Finally, *VDR* plays a dominant role in male fertility as *Vdr*^{-/-} mice show abnormal gonads in both sexes and variable reproductive phenotypes such as reduced sperm count [55]. In humans, two polymorphisms in *VDR* were associated with female idiopathic infertility only [56]. Fertility of patient 3 has not been assessed yet, and we cannot exclude a role of the *VDR* variant in his DSD phenotype. Network analysis by ORVAL predicts a pathogenic gene network between *CHD7*, *MYO7A* and *GLI2* (S1 Fig).

8 / 17

Table 2. Additional gene variants identified in the DSD patients harboring the *NR5A1/SF-1* p.Gly146Ala variant.

Patient	Chromosome position	Gene (Name)	Variant	Type	dbSNP	Zygosity	Previously reported ^a	Inheritance pattern ^b
1	4:1807384	<i>FGFR3</i> (Fibroblast Growth Factor Receptor 3)	c.1633_1634del; p.Cys545Hisfs*17	frameshift deletion	ND	het		AD/AR
	5:5232601	<i>ADAMTS16</i> (ADAM Metallopeptidase with Thrombospondin Type 1 Motif 16)	c.1822_1823del; p.His608*	stopgain	ND	het		ND
	19:7184641	<i>INSR</i> (Insulin Receptor)	c.660_661del; p.Pro220Hisfs*4	frameshift deletion	ND	het		AD/AR
3	2:120989442	<i>GLI2</i> (GLI Family Zinc Finger 2)	c.3528G>T; p.Gln1176His	nonsynonymous SNV	rs139686081	het		AD
	8:60743055	<i>CHD7</i> (Chromodomain Helicase DNA Binding Protein 7)	c.1623C>A; p.His541Gln	nonsynonymous SNV	ND	het		AD
	11:77181567	<i>MYO7A</i> (Myosin VIIA)	c.2882G>A; p.Gly961Asp	nonsynonymous SNV	rs199575418	het		AD/AR
	12:47865148	<i>VDR</i> (Vitamin D Receptor)	c.176C>T; p.Thr59Ile	nonsynonymous SNV	rs145002466	het		AR
6	10:33330774	<i>NRP1</i> (Neuropilin 1)	c.182C>A; p.Pro61Gln	nonsynonymous SNV	ND	het		ND
8	2:48698724	<i>LHCGR</i> (Luteinizing Hormone/Choriogonadotropin Receptor)	c.757T>C; p.Ser253Pro	nonsynonymous SNV	ND	hom		AD/AR
9	9:114275766	<i>COL27A1</i> (Collagen Type XXVII Alpha 1 Chain)	c.3715C>T; p.Arg1239Trp	nonsynonymous SNV	rs143724625	het		AR
	15:41564270	<i>TYRO3</i> (TYRO3 Protein Tyrosine Kinase)	c.666_667insCACTGCCTGCAGCCC CCTTCAACATCACC; p. Ala223Hisfs*21	frameshift insertion	ND	het		ND
10	16:984721	<i>SOX8</i> (SRY-Box Transcription Factor 8)	c.676A>C; p.Thr226Pro	nonsynonymous SNV	ND	het		ND
11	7:75985941	<i>POR</i> (Cytochrome P450 Oxidoreductase)	c.1679C>T; p.Thr560Met	nonsynonymous SNV	rs574694698	het		AR
	16:2114399	<i>PKD1</i> (Polycystin 1, Transient Receptor Potential Channel Interacting)	c.2624C>T; p.Pro875Leu	nonsynonymous SNV	ND	het		AD
	16:30737182	<i>SRCAP</i> (Snf2 Related CREBBP Activator Protein)	c.7142G>A; p.Arg2381His	nonsynonymous SNV	rs765139685	het		AD
	17:72123563	<i>SOX9</i> (SRY-Box Transcription Factor 9)	c.710dup; p.Pro238Thrfs*14	frameshift insertion	ND	het	Campomelic dysplasia [42]	AD
12	X:67721837	<i>AR</i> (Androgen Receptor)	c.2323C>T; p.Arg775Cys	nonsynonymous SNV	rs137852562	hemi	AIS [43]	XLR

(Continued)

Table 2. (Continued)

Patient	Chromosome position	Gene (Name)	Variant	Type	dbSNP	Zygosity	Previously reported ^a	Inheritance pattern ^b
13	11:77194460	<i>MYO7A</i> (Myosin VIIA)	c.4259G>A; p.Arg1420His	nonsynonymous SNV	rs568337942	het		AD/AR
	16:984739	<i>SOX8</i> (SRY-Box Transcription Factor 8)	c.694A>C; p.Lys232Gln	nonsynonymous SNV	rs1596200787	het		ND

AD, autosomal dominant; AIS, androgen insensitivity syndrome; AR, autosomal recessive; Hemi, hemizygous; Het, heterozygous; Hom, homozygous; ND, not determined; POI, primary ovarian insufficiency; XLR, X-linked recessive.

Variants classified as pathogenic, likely pathogenic or as of unknown significance according to the ACMG (American College of Medical Genetics) are highlighted in bold.

^aPreviously associated disease to the specific variant identified in this work.

^bInheritance pattern of each gene according to OMIM (Online Mendelian Inheritance in Man).

<https://doi.org/10.1371/journal.pone.0287515.t002>

[51] and a 46,XY male presenting with penoscrotal hypospadias, in whom other genetic variants were identified, among them a variant in *MAMLD1*, a known DSD-related gene [54].

In 46,XY patient 8 with a phenotype of opposite sex a homozygous, inactivating variant in *LHCGR* (c.757T>C; p.Ser253Pro) was found. This variant has been previously reported to severely reduce the signal transduction activity of the LH receptor and therefore leads to the complete form of Leydig cell hypoplasia (LCH) as suspected in patient 8 [58].

A missense variant in *COL27A1* (c.3715C>T; p.Arg1239Trp) and a frameshift insertion in *TYRO3* (c.666_667insCACTGCCTGCAGCCCCCTTCAACATCACC; p.Ala223HisfsTer21) were found in patient 9. Both variants were categorized as VUS and were detected in heterozygosis. In mice, *Col27a1* is highly expressed in XY somatic supporter cells compared to XX during the earliest stages of gonad development [59]. *Col27a1* has been identified as a SRY target gene in the embryonic mouse gonads at E11.5 by ChIP-Chip experiments [53]. Similarly, *Tyro3* is overexpressed in male somatic cells [60], and is regulated by SOX9 [53]. Protein truncating variants of *TYRO3* were found in individuals with idiopathic hypogonadotropic hypogonadism establishing a role of this gene in reproductive development [61]. Taken together, the data suggest that both *COL27A1* and *TYRO3* genes might be part of the genetic network underlying the early stages of mammalian fetal gonadal development. However, additional studies are needed to verify that these genetic variants are causing the ovotesticular DSD phenotype in patient 10. Moreover, a gene interaction between *COL27A1* and *TYRO3* was not predicted by ORVAL.

In 46,XY patient 10 with a distal hypospadias, one missense variant in the *SOX8* (c.676A>C; p.Thr226Pro) gene was detected. It was identified in heterozygosis and was classified as VUS. *SOX8* is involved in early testis determination [62]. *SOX8* gene variants are associated with a range of phenotypes including 46,XY DSD and human reproductive anomalies in males and females [63]. Single-nucleotide variants (SNV) associated with 46,XY gonadal dysgenesis are mostly located in the HMG-box of *SOX8* [49], while those reported in infertile patients flank the HMG-box or localize to one of the transactivation domains (TA) [64]. However, more recently, a missense variant in the TA2 region of *SOX8* was identified in a 46,XY patient with gonadal dysgenesis [49]. The novel c.676A>C; p.Thr226Pro variant is located in the first TA of the protein. In vitro studies have shown impaired cellular localization in some mutant proteins located in this functional domain of *SOX8*. Therefore, this missense variant likely explains the genital phenotype observed in patient 10. At age 14 years, biochemical assessment of the HPG axis was normal and pubertal development was ongoing (Tanner 3–4).

Four heterozygous VUS or likely pathogenic variants were identified in patient 11 with a severe 46,XY DSD phenotype. These were *POR* (c.1679C>T; p.Thr560Met), *PKD1* (c.2624C>T; p.Pro875Leu), *SRCAP* (c.7142G>A; p.Arg2381His) and *SOX9* (c.710dup; p.Pro238Thrfs*14). The involvement of *POR* and *SOX9* in sexual development is well known and several sequence variants have been described in 46,XY DSD patients [30,53,65]. The patient showed the missense *POR* p.Thr560Met variant in compound heterozygosity with the p.Ala500Val (c.1499C>T) polymorphism. A previous report suggested that the combination of a pathogenic *POR* variant and a polymorphism may cause CAH [66]. However, to confirm a disease-causing effect of the *POR* variants for the DSD phenotype in our patient, functional studies including the specific variants would be needed. *Pkd1* is critical for epididymal epithelium development and for maintaining mice male reproductive tract [67]. *PKD1* variants have not been related to DSD yet, but they cause autosomal dominant polycystic kidney disease (ADPKD), which involves reproductive tract abnormalities and infertility in males [63]. Therefore, a role of *PKD1* variants in DSD seems possible. Likewise, the role of *SRCAP* in sex differentiation and development is unknown. However, this is the second 46,XY DSD patient in whom a gene variant is identified [48]. According to ORVAL analysis, oligogenic pathogenicity is predicted by combination of variants in a gene network including *POR*, *PKD1* and *SRCAP* (S1 Fig).

In patient 12, we identified an *AR* variant (c.2323C>T; p.Arg775Cys) previously reported in a patient with Complete Androgen Insensitivity Syndrome (CAIS) [43]. Because the patient presented with a typical CAIS phenotype, it seems plausible that this hemizygous *AR* variant is fully responsible for the DSD.

Patient 13, with a severe 46,XY phenotype, harbored two heterozygous missense variants in *MYO7A* and *SOX8* genes. Both were categorized as VUS by the ACMG. As in patient 10, the *SOX8* variant (c.694A>C; p.Lys232Gln) was also located in the TA1 domain of the protein. However, the phenotype of patient 13 was more severe, either caused by the *SOX8* variant alone or due to the digenic effect together with *MYO7A*. Importantly, the combination of variants in *SOX8* and *MYO7A* is predicted as disease-causing by ORVAL (S1 Fig). The combination of variants in *MYO7A* and *SOX8* in DSD was reported previously [50,54], and suggests that the broad phenotype observed in DSD individuals might be explained by oligogenic origin [2].

In four patients carrying the heterozygous p.Gly146Ala *NR5A1* variant, the WES and specific data analysis revealed no other candidate genes explaining their DSD phenotype. Of these patients 2, 4 and 5 had a 46,XX karyotype and an opposite genital phenotype, and were assigned as males at birth, whereas patient 7 presented with a severe 46,XY DSD. All of them had no other organ anomalies. Although NGS has facilitated the identification of the underlying genetic defects of DSD, about 50% of individuals with a 46,XY DSD remain without a molecular diagnosis with currently used methods [30]. We used WES in our study, while other genetic studies also search for variants in noncoding, regulatory or intronic regions by whole genome sequencing (WGS). But even when using WGS, a considerable number of patients are still reportedly unsolved [68]. Thus, other factors such as environmental factors or epigenetic regulators have been suggested playing a role [68,69]. In addition, oligogenic or even polygenic inheritance might be considered for explaining the broad phenotypes seen in some individuals with a DSD [3,26–32,54,70–73]. In early days of genetic workup of DSD, patients were studied by candidate Sanger sequencing. In 46,XY DSD subjects typical candidates were the *AR*, *SRD5A2* and *NR5A1*/SF-1; and once a genetic variant was found, additional genes were not tested. Thus, some DSD patients that have been tested by the candidate approach may not have a correct diagnosis and need to be retested by NGS.

Our study suffers from some limitations. The disease-causing effect of identified variants was assessed with bioinformatics tools and the current knowledge from literature only. Ideally,

novel genetic variants should be functionally tested for definite proof of their pathogenic effect. But this is not an easy task when finding multiple candidates, as both cell models as well as animal models have their limitations. We and others try to overcome this obstacle in the near future by using patient-derived fibroblasts comprising the original (complex) genetic background and reprogramming into corresponding gonadal and adrenal cell lines for mechanistic studies [74]. Additionally, trio exome or parental sequencing would help to assess the mode of inheritance and the clinical relevance of variants by looking at genotype-phenotype correlations, but unfortunately DNA of relatives is not always available (as in our case).

In conclusion, NGS genetic analysis of DSD individuals carrying the p.Gly146Ala variant of the *NR5A1*/SF-1 gene revealed variants in other genes (likely) explaining their phenotype. These gene variants were either found in established DSD genes, were previously described or novel, and were (likely) disease-causing either in a monogenic or in a suggested oligogenic fashion. Although we were not able to find causal genetic variants in four out of 13 DSD individuals carrying the *NR5A1*/SF-1 p.Gly146Ala, our study supports the claim that this *NR5A1*/SF-1 variant is a benign polymorphism that does not play a role in the pathogenesis of DSD. Therefore, we strongly recommend reanalyzing DSD patients whose phenotype has been thought to be explained by this variant in order to find the real underlying genetic cause.

Supporting information

S1 Fig. Potential oligogenic interaction networks of DSD- and *NR5A1*-related genes identified in specific DSD individuals harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. Networks were identified for patients 3, 11 and 13 respectively. To search for potential oligogenic disease networks, the Oligogenic Resource for Variant Analysis (ORVAL, <https://orval.ibsquare.be/>) was used. Nodes represent genes and edges connect two genes only, if between them there is at least one candidate disease-causing variant combination predicted by VarCoPP. The colour of the edge represents the pathogenicity score for that pair of genes. This score is represented in a colour range from brown (higher pathogenicity score) to yellow (lower pathogenicity score).

(DOCX)

S1 Table. Genes included in the customized DSD panel and their suggested role in DSD. CHH, central causes of hypogonadism; G det, gonadal determination; G diff, gonadal differentiation.

(DOCX)

S2 Table. Complete description of the phenotype and biochemical data of the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. ACTH, adrenocorticotrophic hormone; AMH, anti-Müllerian hormone; d, days; DHEA-S, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; mo, month; N, normal; ND, not determined; PRL, prolactin; P4, progesterone; Y, years; Δ 4-A, delta 4-androstenedione; 17OHP4, 17-hydroxy-progesterone. (*) Values after stimulation with hCG or ACTH. Out of range values for karyotypic sex and age are given in bold.

(DOCX)

S3 Table. Gene variant characterization: Allele frequency and disease prediction by ACMG classification and by different *in silico* programs. B, benign; Dam, damaging; DC, disease causing; Dis, disease; LB, likely benign; LP, likely pathogenic; N, neutral; ND, not determined; P, polymorphism; Path, pathogenic; Psdam, possibly damaging; Prben, probably benign; Prdam, probably damaging; VUS, variant of unknown significance. ^aSpecific allele frequency

for the origin and karyotype of the patient. ^bCADD phred score >20 indicates that the variant is predicted to be the 1% most deleterious substitution that you can do to the human genome. For each gene, sequence information is based on: *ADAMTS16* (NM_139056.4), *AR* (NM_000044.3), *CHD7* (NM_017780.4), *COL27A1* (NM_032888.4), *FGFR3* (NM_000142.5), *GLI2* (NM_001374353.1), *INSR* (NM_000208.4), *LHCGR* (NM_000233.4), *MYO7A* (NM_000260.4), *NRP1* (NM_003873.7), *PKD1* (NM_001009944.3), *POR* (NM_001395413.1), *SOX8* (NM_014587.5), *SOX9* (NM_000346.4), *SRCAP* (NM_006662.3), *TYRO3* (NM_006293.4) and *VDR* (NM_000376.3).
(DOCX)

S4 Table. List of rejected variants identified in the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. Variants were discarded after filtering due to weak relation to DSD, zygosity or absence of correspondence to the phenotype. B, benign; Het, heterozygous; Hom, homozygous; LB, likely benign; LP, likely pathogenic; ND, not determined; P, pathogenic; G6PDH, glucose-6-phosphate dehydrogenase; VUS, variant of unknown significance. For each gene, sequence information is based on: *ADCY7* (NM_001114.5), *AMH* (NM_000479.5), *ARVCF* (NM_001670.3), *ATM* (NM_000051.4), *ATR* (NM_001184.4), *BBS5* (NM_152384.3), *CDH1* (NM_004360.5), *CEBPB* (NM_005194.4), *COL9A3* (NM_001853.4), *DHCR24* (NM_014762.4), *EXO1* (NM_130398.4), *FOXO3* (NM_001455.4), *G6PD* (NM_001360016.2), *GEMIN4* (NM_015721.3), *GHR* (NM_000163.5), *GPR83* (NM_016540.4), *GRIN2C* (NM_000835.6), *HFE* (NM_000410.4), *IFFO1* (NM_001193457.2), *IL6ST* (NM_002184.4), *INPP5F* (NM_014937.4), *ITIH3* (NM_002217.4), *KYAT3* (NM_001008661.3), *MKSI* (NM_017777.4), *MTRR* (NM_002454.3), *NBN* (NM_002485.5), *NCOA3* (NM_181659.3), *NF1* (NM_001042492.3), *NOBOX* (NM_001080413.3), *POLG* (NM_002693.3), *POLM* (NM_013284.4), *PPIL2* (NM_014337.4), *ROS1* (NM_001378902.1), *SARDH* (NM_001134707.2), *STAG3* (NM_001282717.2), *THBD* (NM_000361.3), *UBR2* (NM_001363705.2), *VPS18* (NM_020857.3) and *ZMIZ2* (NM_031449.4).
(DOCX)

Acknowledgments

The authors thank the patients and their families for participating in our research.

Author Contributions

Conceptualization: Idoia Martinez de Lapiscina, Mirian Sanchez, Christa E. Flück.

Data curation: Idoia Martinez de Lapiscina, Christa E. Flück.

Funding acquisition: Idoia Martinez de Lapiscina, Luis Castaño, Christa E. Flück.

Investigation: Idoia Martinez de Lapiscina, Luis Castaño, Christa E. Flück.

Methodology: Idoia Martinez de Lapiscina, Chrysanthi Kouri, Mirian Sanchez, Núria Camats.

Resources: Gema Grau, Itxaso Rica, Amaia Rodriguez, Amaia Vela, Alicia Cortazar, Maria Concepción Alonso-Cerezo, Pilar Bahillo, Laura Bertholt, Isabel Esteva, Luis Castaño.

Software: Idoia Martinez de Lapiscina, Chrysanthi Kouri, Josu Aurrekoetxea.

Supervision: Luis Castaño, Christa E. Flück.

Writing – original draft: Idoia Martinez de Lapiscina, Christa E. Flück.

Writing – review & editing: Idoia Martinez de Lapiscina, Chrysanthi Kouri, Josu Aurrekoetxea, Mirian Sanchez, Rawda Naamneh Elzenaty, Kay-Sara Sauter, Núria Camats, Gema

Grau, Itxaso Rica, Amaia Rodriguez, Amaia Vela, Alicia Cortazar, Maria Concepción Alonso-Cerezo, Pilar Bahillo, Laura Bertholt, Isabel Esteve, Luis Castaño, Christa E. Flück.

References

1. Cools M, Nordenström A, Robeva R, Hall J, Westerveld P, Flück C, et al. Caring for individuals with a difference of sex development (DSD): a Consensus Statement. *Nat Rev Endocrinol*. 2018 Jul; 14(7):415–429. <https://doi.org/10.1038/s41574-018-0010-8> PMID: 29769693
2. Camats N, Flück CE, Audi L. Oligogenic origin of differences of sex development in humans. *Int J Mol Sci*. 2020 Mar 6; 21(5):1809. <https://doi.org/10.3390/ijms21051809> PMID: 32155719
3. Martinez de LaPiscina I, Flück CE. Genetics of human sexual development and related disorders. *Curr Opin Pediatr*. 2021 Dec 1; 33(6):556–563. <https://doi.org/10.1097/MOP.0000000000001066> PMID: 34654048
4. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development. *Nat Rev Endocrinol*. 2014 Nov; 10(11):673–83. <https://doi.org/10.1038/nrendo.2014.163> PMID: 25246082
5. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al. Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. *J Clin Endocrinol Metab*. 2002 Apr; 87(4):1829–33. <https://doi.org/10.1210/jcem.87.4.8376> PMID: 11932325
6. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. *Nat Genet*. 1999 Jun; 22(2):125–6. <https://doi.org/10.1038/9629> PMID: 10369247
7. Fabbri-Scallet H, de Sousa LM, Maciel-Guerra AT, Guerra-Júnior G, de Mello MP. Mutation update for the NR5A1 gene involved in DSD and infertility. *Hum Mutat*. 2020 Jan; 41(1):58–68. <https://doi.org/10.1002/humu.23916> PMID: 31513305
8. Domenice S, Machado AZ, Ferreira FM, Ferraz-de-Souza B, Lerario AM, Lin L, et al. Wide spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. *Birth Defects Res C Embryo Today*. 2016 Dec; 108(4):309–320. <https://doi.org/10.1002/bdrc.21145> PMID: 28033660
9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May; 17(5):405–24. <https://doi.org/10.1038/gim.2015.30> PMID: 25741868
10. WuQiang F, Yanase T, Wei L, Oba K, Nomura M, Okabe T, et al. Functional characterization of a new human Ad4BP/SF-1 variation, G146A. *Biochem Biophys Res Commun*. 2003 Nov 28; 311(4):987–94. <https://doi.org/10.1016/j.bbrc.2003.10.096> PMID: 14623279
11. Wada Y, Okada M, Fukami M, Sasagawa I, Ogata T. Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1. *Fertil Steril*. 2006 Mar; 85(3):787–90. <https://doi.org/10.1016/j.fertnstert.2005.09.016> PMID: 16500365
12. Paris F, De Ferran K, Bhangoo A, Ten S, Lahlou N, Audran F, et al. Isolated “idiopathic” micropenis: hidden genetic defects? *Int J Androl*. 2011 Dec; 34(6 Pt 2):e518–25. <https://doi.org/10.1111/j.1365-2605.2010.01135.x> PMID: 21535007
13. Wada Y, Okada M, Hasegawa T, Ogata T. Association of severe micropenis with Gly146Ala polymorphism in the gene for steroidogenic factor-1. *Endocr J*. 2005 Aug; 52(4):445–8. <https://doi.org/10.1507/endocrj.52.445> PMID: 16127213
14. Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, Montjean D, et al. Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. *Am J Hum Genet*. 2010 Oct 8; 87(4):505–12. <https://doi.org/10.1016/j.ajhg.2010.09.009> PMID: 20887963
15. Röpke A, Tewes AC, Gromoll J, Kliesch S, Wieacker P, Tüttelmann F. Comprehensive sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile males. *Eur J Hum Genet*. 2013 Sep; 21(9):1012–5. <https://doi.org/10.1038/ejhg.2012.290> PMID: 23299922
16. Philibert P, Paris F, Lakhal B, Audran F, Gaspari L, Saâd A, et al. NR5A1 (SF-1) gene variants in a group of 26 young women with XX primary ovarian insufficiency. *Fertil Steril*. 2013 Feb; 99(2):484–9. <https://doi.org/10.1016/j.fertnstert.2012.10.026> PMID: 23153500
17. Liu W, Liu M, Fan W, Nawata H, Yanase T. The Gly146Ala variation in human SF-1 gene: its association with insulin resistance and type 2 diabetes in Chinese. *Diabetes Res Clin Pract*. 2006 Sep; 73(3):322–8. <https://doi.org/10.1016/j.diabres.2006.02.007> PMID: 16564598
18. Camats N, Pandey A V., Fernández-Cancio M, Andaluz P, Janner M, Torán N, et al. Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,

- XX individuals. *J Clin Endocrinol Metab*. 2012 Jul; 97(7):E1294–306. <https://doi.org/10.1210/jc.2011-3169> PMID: 22549935
19. Tantawy S, Mazen I, Soliman H, Anwar G, Atef A, El-Gammal M, et al. Analysis of the gene coding for steroidogenic factor 1 (SF1, NR5A1) in a cohort of 50 Egyptian patients with 46,XY disorders of sex development. *Eur J Endocrinol*. 2014 Apr 10; 170(5):759–67. <https://doi.org/10.1530/EJE-13-0965> PMID: 24591553
 20. Reuter AL, Goji K, Bingham NC, Matsuo M, Parker KL. A novel mutation in the accessory DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal insufficiency. *Eur J Endocrinol*. 2007 Aug; 157(2):233–8. <https://doi.org/10.1530/EJE-07-0113> PMID: 17656604
 21. Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schröder V, et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. *Hum Mutat*. 2008 Jan; 29(1):59–64. <https://doi.org/10.1002/humu.20588> PMID: 17694559
 22. Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, Fukutani K, et al. Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1. *J Clin Endocrinol Metab*. 2004 Dec; 89(12):5930–5. <https://doi.org/10.1210/jc.2004-0935> PMID: 15579739
 23. Bertelloni S, Dati E, Baldinotti F, Toschi B, Marrocco G, Sessa MR, et al. NR5A1 Gene Mutations: Clinical, Endocrine and Genetic Features in Two Girls with 46,XY Disorder of Sex Development. *Horm Res Paediatr*. 2014; 81(2):104–8. <https://doi.org/10.1159/000354990> PMID: 24434652
 24. Woo KH, Cheon B, Kim JH, Cho J, Kim GH, Yoo HW, et al. Novel Heterozygous Mutations of NR5A1 and Their Functional Characteristics in Patients with 46,XY Disorders of Sex Development without Adrenal Insufficiency. *Horm Res Paediatr*. 2015; 84(2):116–23. <https://doi.org/10.1159/000431324> PMID: 26139438
 25. Adamovic T, Chen Y, Thai HTT, Zhang X, Markljung E, Zhao S, et al. The p.G146A and p.P125P polymorphisms in the steroidogenic factor-1 (SF-1) gene do not affect the risk for hypospadias in Caucasians. *Sex Dev*. 2012; 6(6):292–7. <https://doi.org/10.1159/000343782> PMID: 23154282
 26. Camats N, Fernández-Cancio M, Audi L, Schaller A, Flück CE. Broad phenotypes in heterozygous NR5A1 46,XY patients with a disorder of sex development: an oligogenic origin? *Eur J Hum Genet*. 2018 Sep; 26(9):1329–1338. <https://doi.org/10.1038/s41431-018-0202-7> PMID: 29891883
 27. de LaPiscina IM, Mahmoud RAA, Sauter KS, Esteve I, Alonso M, Costa I, et al. Variants of STAR, AMH and ZFPM2/FOG2 may contribute towards the broad phenotype observed in 46,XY DSD patients with heterozygous variants of NR5A1. *Int J Mol Sci*. 2020 Nov 13; 21(22):8554. <https://doi.org/10.3390/ijms21228554> PMID: 33202802
 28. Mazen I, Abdel-Hamid M, Mekawy M, Bignon-Topalovic J, Boudjenah R, El Gammal M, et al. Identification of NR5A1 mutations and possible digenic inheritance in 46,XY gonadal dysgenesis. *Sex Dev*. 2016; 10(3):147–51. <https://doi.org/10.1159/000445983> PMID: 27169744
 29. Werner R, Möning I, Lünstedt R, Wünsch L, Thorns C, Reiz B, et al. New NR5A1 mutations and phenotypic variations of gonadal dysgenesis. *PLoS One*. 2017 May 1; 12(5):e0176720. <https://doi.org/10.1371/journal.pone.0176720> PMID: 28459839
 30. Eggers S, Sadein S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort. *Genome Biol*. 2016 Nov 29; 17(1):243. <https://doi.org/10.1186/s13059-016-1105-y> PMID: 27899157
 31. Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development. *Hum Mutat*. 2018 Jan; 39(1):124–139. <https://doi.org/10.1002/humu.23354> PMID: 29027299
 32. Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes. *Hum Genet*. 2018 Mar; 137(3):265–277. <https://doi.org/10.1007/s00439-018-1879-y> PMID: 29582157
 33. 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). *Horm Res Paediatr* [Internet]. 2022;95(suppl 2(2):1–616.
 34. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2010 Mar 1; 26(5):589–95. <https://doi.org/10.1093/bioinformatics/btp698> PMID: 20080505
 35. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics*. 2013; 43(1110):11.10.1–11.10.33. <https://doi.org/10.1002/0471250953.bi1110s43> PMID: 25431634
 36. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nat Protoc*. 2015 Oct; 10(10):1556–66. <https://doi.org/10.1038/nprot.2015.105> PMID: 26379229

37. Meynert AM, Ansari M, FitzPatrick DR, Taylor MS. Variant detection sensitivity and biases in whole genome and exome sequencing. *BMC Bioinformatics*. 2014 Jul 19; 15(1):247. <https://doi.org/10.1186/1471-2105-15-247> PMID: 25038816
38. Arteche-López A, Ávila-Fernández A, Romero R, Riveiro-Álvarez R, López-Martínez MA, Giménez-Pardo A, et al. Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. *Sci Rep*. 2021 Mar 11; 11(1):5697. <https://doi.org/10.1038/s41598-021-85182-w> PMID: 33707547
39. De Cario R, Kura A, Suraci S, Magi A, Volta A, Marcucci R, et al. Sanger Validation of High-Throughput Sequencing in Genetic Diagnosis: Still the Best Practice? *Front Genet*. 2020 Dec 2; 11:592588. <https://doi.org/10.3389/fgene.2020.592588> PMID: 33343633
40. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. *Bioinformatics*. 2019 Jun 1; 35(11):1978–1980. <https://doi.org/10.1093/bioinformatics/bty897> PMID: 30376034
41. Renaux A, Papadimitriou S, Versbraegen N, Nachtegaal C, Boutry S, Nowé A, et al. ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations. *Nucleic Acids Res*. 2019 Jul 2; 47(W1):W93–W98. <https://doi.org/10.1093/nar/gkz437> PMID: 31147699
42. Gentilin B, Forzano F, Bedeschi MF, Rizzuti T, Faravelli F, Izzi C, et al. Phenotype of five cases of prenatally diagnosed campomelic dysplasia harboring novel mutations of the SOX9 gene. *Ultrasound Obstet Gynecol*. 2010 Sep; 36(3):315–23. <https://doi.org/10.1002/uog.7761> PMID: 20812307
43. Brown TR, Lubahn DB, Wilson EM, French FS, Migeon CJ, Corden JL. Functional characterization of naturally occurring mutant androgen receptors from subjects with complete androgen insensitivity. *Mol Endocrinol*. 1990 Dec; 4(12):1759–72. <https://doi.org/10.1210/mend-4-12-1759> PMID: 2082179
44. Ewen KA, Olesen IA, Winge SB, Nielsen AR, Nielsen JE, Graem N, et al. Expression of FGFR3 during human testis development and in germ cell-derived tumours of young adults. *Int J Dev Biol*. 2013; 57(2–4):141–51. <https://doi.org/10.1387/ijdb.130022er> PMID: 23784824
45. Pitetti JL, Calvel P, Zimmermann C, Conne B, Papaioannou MD, Aubry F, et al. An essential role for insulin and IGF1 receptors in regulating sertoli cell proliferation, testis size, and FSH action in mice. *Mol Endocrinol*. 2013 May; 27(5):814–27. <https://doi.org/10.1210/me.2012-1258> PMID: 23518924
46. Jacobi CLJ, Rudigier LJ, Scholz H, Kirschner KM. Transcriptional regulation by the Wilms tumor protein, Wt1, suggests a role of the metalloproteinase Adamts16 in murine genitourinary development. *J Biol Chem*. 2013 Jun 28; 288(26):18811–24. <https://doi.org/10.1074/jbc.M113.464644> PMID: 23661704
47. Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura EE, Eskin A, et al. Identification of novel candidate genes for 46,XY disorders of sex development (DSD) using a C57BL/6J-Y (POS) mouse model. *Biol Sex Differ*. 2018 Jan 30; 9(1):8. <https://doi.org/10.1186/s13293-018-0167-9> PMID: 29378665
48. Globa E, Zelinska N, Shcherbak Y, Bignon-Topalovic J, Bashamboo A, MEIreavey K. Disorders of Sex Development in a Large Ukrainian Cohort: Clinical Diversity and Genetic Findings. *Front Endocrinol (Lausanne)*. 2022 Mar 21; 13:810782. <https://doi.org/10.3389/fendo.2022.810782> PMID: 35432193
49. Zidoune H, Ladjouze A, Chellat-Rezgoune D, Boukri A, Dib SA, Nouri N, et al. Novel Genomic Variants, Atypical Phenotypes and Evidence of a Digenic/Oligogenic Contribution to Disorders/Differences of Sex Development in a Large North African Cohort. *Front Genet*. 2022 Aug 30; 13:900574. <https://doi.org/10.3389/fgene.2022.900574> PMID: 36110220
50. Li L, Gao F, Fan L, Su C, Liang X, Gong C. Disorders of Sex Development in Individuals Harboring MAMLD1 Variants: WES and Interactome Evidence of Oligogenic Inheritance. *Front Endocrinol (Lausanne)*. 2020 Dec 23; 11:582516. <https://doi.org/10.3389/fendo.2020.582516> PMID: 33424767
51. Baxter RM, Arboleda VA, Lee H, Barseghyan H, Adam MP, Fechner PY, et al. Exome sequencing for the diagnosis of 46, XY disorders of sex development. *J Clin Endocrinol Metab*. 2015 Feb; 100(2):E333–44. <https://doi.org/10.1210/jc.2014-2605> PMID: 25383892
52. Jameson SA, Lin YT, Capel B. Testis development requires the repression of Wnt4 by Fgf signaling. *Dev Biol*. 2012 Oct 1; 370(1):24–32. <https://doi.org/10.1016/j.ydbio.2012.06.009> PMID: 22705479
53. Li Y, Zheng M, Lau YFC. The sex-determining factors SRY and SOX9 regulate similar target genes and promote testis cord formation during testicular differentiation. *Cell Rep*. 2014 Aug 7; 8(3):723–33. <https://doi.org/10.1016/j.celrep.2014.06.055> PMID: 25088423
54. Flück CE, Audí L, Fernández-Cancio M, Sauter KS, Martínez de LaPiscina I, Castaño L, et al. Broad Phenotypes of Disorders/Differences of Sex Development in MAMLD1 Patients Through Oligogenic Disease. *Front Genet*. 2019 Aug 29; 10:746. <https://doi.org/10.3389/fgene.2019.00746> PMID: 31555317
55. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. *Endocrinology*. 2000 Apr; 141(4):1317–24. <https://doi.org/10.1210/endo.141.4.7403> PMID: 10746634

56. Djurovic J, Stamenkovic G, Todorovic J, Aleksic N, Stojkovic O. Polymorphisms and haplotypes in VDR gene are associated with female idiopathic infertility. *Hum Fertil (Camb)*. 2020 Jun; 23(2):101–110. <https://doi.org/10.1080/14647273.2018.1515503> PMID: 30221569
57. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG, Ruhrberg C. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism. *Hum Mol Genet*. 2011 Jan 15; 20(2):336–44. <https://doi.org/10.1093/hmg/ddq468> PMID: 21059704
58. Qiao J, Han B. Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin receptor. *Prog Mol Biol Transl Sci*. 2019; 161:69–89. <https://doi.org/10.1016/bs.pmbts.2018.09.007> PMID: 30711030
59. Bouma GJ, Hudson QJ, Washburn LL, Eicher EM. New candidate genes identified for controlling mouse gonadal sex determination and the early stages of granulosa and Sertoli cell differentiation. *Biol Reprod*. 2010 Feb; 82(2):380–9. <https://doi.org/10.1095/biolreprod.109.079822> PMID: 19864314
60. Beverdam A, Koopman P. Expression profiling of purified mouse gonadal somatic cells during the critical time window of sex determination reveals novel candidate genes for human sexual dysgenesis syndromes. *Hum Mol Genet*. 2006 Feb 1; 15(3):417–31. <https://doi.org/10.1093/hmg/ddi463> PMID: 16399799
61. Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare Variants Identified through Exome Sequencing via Publicly Available Control Data. *Am J Hum Genet*. 2018 Oct 4; 103(4):522–534. <https://doi.org/10.1016/j.ajhg.2018.08.016> PMID: 30269813
62. Eggers S, Sinclair A. Mammalian sex determination—insights from humans and mice. *Chromosome Res*. 2012 Jan; 20(1):215–38. <https://doi.org/10.1007/s10577-012-9274-3> PMID: 22290220
63. Liu B, Chen SC, Yang YM, Yan K, Qian YQ, Zhang JY, et al. Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease. *Sci Rep*. 2015 Dec 3; 5:17468. <https://doi.org/10.1038/srep17468> PMID: 26632257
64. Portnoi MF, Dumargne MC, Rojo S, Witchel SF, Duncan AJ, Eozenou C, et al. Mutations involving the SRY-related gene SOX8 are associated with a spectrum of human reproductive anomalies. *Hum Mol Genet*. 2018 Apr 1; 27(7):1228–1240. <https://doi.org/10.1093/hmg/ddy037> PMID: 29373757
65. Miller WL, Huang N, Pandey A V, Flück CE, Agrawal V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. *Ann N Y Acad Sci*. 2005 Dec; 1061:100–8. <https://doi.org/10.1196/annals.1336.012> PMID: 16467261
66. Gusmano C, Cannarella R, Crafa A, Barbagallo F, La Vignera S, Condorelli RA, et al. Congenital adrenal hyperplasia, disorders of sex development, and infertility in patients with POR gene pathogenic variants: a systematic review of the literature. *J Endocrinol Invest*. 2023 Jan; 46(1):1–14. <https://doi.org/10.1007/s40618-022-01849-9> PMID: 35842891
67. Nie X, Arend LJ. Pkd1 is required for male reproductive tract development. *Mech Dev*. 2013 Nov-Dec; 130(11–12):567–76. <https://doi.org/10.1016/j.mod.2013.07.006> PMID: 23933588
68. Délot EC, Vilain E. Towards improved genetic diagnosis of human differences of sex development. *Nat Rev Genet*. 2021 Sep; 22(9):588–602. <https://doi.org/10.1038/s41576-021-00365-5> PMID: 34083777
69. Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The genetic and environmental factors underlying hypospadias. *Sex Dev*. 2015; 9(5):239–259. <https://doi.org/10.1159/000441988> PMID: 26613581
70. Zhang W, Shi J, Zhang C, Jiang X, Wang J, Wang W, et al. Identification of gene variants in 130 Han Chinese patients with hypospadias by targeted next-generation sequencing. *Mol Genet Genomic Med*. 2019 Aug; 7(8):e827. <https://doi.org/10.1002/mgg3.827> PMID: 31219235
71. Kolesinska Z, Acierno J Jr, Ahmed SF, Xu C, Kapczuk K, Skorzysk-Werner A, et al. Integrating clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development. *Endocr Connect*. 2018 Dec; 7(12):1480–1490. <https://doi.org/10.1530/EC-18-0472> PMID: 30496128
72. Camats N, Flück CE, Audi L. Oligogenic Origin of Differences of Sex Development in Humans. *Int J Mol Sci*. 2020 Mar 6; 21(5):1809. <https://doi.org/10.3390/ijms21051809> PMID: 32155719
73. de LaPiscina IM, de Mingo C, Riedl S, Rodriguez A, Pandey A V., Fernández-Cancio M, et al. GATA4 variants in individuals with a 46,XY Disorder of Sex Development (DSD) may or may not be associated with cardiac defects depending on second hits in other DSD genes. *Front Endocrinol (Lausanne)*. 2018 Apr 4; 9:142. <https://doi.org/10.3389/fendo.2018.00142> PMID: 29670578
74. Gonen N, Eozenou C, Mitter R, Elzaïat M, Stévant I, Aviram R, et al. In vitro cellular reprogramming to model gonad development and its disorders. *Sci Adv*. 2023 Jan 4; 9(1):eabn9793. <https://doi.org/10.1126/sciadv.abn9793> PMID: 36598988